×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu
Simon Doyle

Simon Doyle

Simon is a senior portfolio manager within the global Multi-Asset team and has specific responsibility for Schroder’s Australian Fixed Income and Multi-Asset Investment capability managing over USD 10 billion in assets. Simon has over 30 years of industry experience joining Schroders in 2003 as Head of Strategy, before assuming overall responsibility for the Australian Multi-Asset capability in 2004. Simon was instrumental in developing Schroders “objective based” investment capability, launching the highly successful Schroder Real Return (CPI+5%) Fund in 2008. In 2016, Simon and his team launched the SISF Global Target Return Fund which uses the same investment process as the long standing Australian strategy but with an objective of achieving returns above USD cash. Simon is the lead portfolio manager for both strategies. Simon holds a Masters in Applied Finance from Macquarie University and a Bachelors degree in Economics from the University of Sydney.

Funds / Video

Future returns under pressure

December 3, 2020December 8, 2020 - by Simon Doyle

Suppressed yields in fixed income and elevated equity valuations have put future returns under pressure. Investment teams have a few choices – take more risk or think differently about how portfolios are structured.

Read More

Recently Added

  • Evening Report: Market surges 1.2%
  • Inauguration Inflation
  • Lunch Report: Aussie market bounces back
  • Optimistic Investing Belies an Uncertain Outlook
  • The Unknown Unknowns
  • Australia…One Hour In…ASX up 67 points
  • ELD – Citi rates the stock as Buy
  • SUL – Credit Suisse rates the stock as Outperform

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Heart.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the House.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Car.